Akkary_edit_Layout 1 06/10/2009 11:43 Page 10
Gastro-oesophageal Reflux Disease
12 months that mental and physical Short Form (SF)-36 scores were bridge therapy between pharmacological therapy and ARP, but are
significantly improved. Importantly, 80% of patients had improved unlikely to replace the existing ARP.
distal oesophageal acid exposure, as evidenced by significantly
decreased DeMeester scores (from 44 to 30; p<0.001). Moreover, Conclusion
the majority of patients (68%) were off PPIs at 12-month follow-up. GORD represents a physiological and anatomical disorder of the LOS.
A recent study evaluating the use of the NDO Plicator and Stretta The diagnostic work-up includes barium oesophagram, upper
procedure in the obese population found a significant overall failure gastrointestinal endoscopy, pH monitoring and oesophageal
rate (28%). The study demonstrated only modest reductions in manometry. To date, in selected patients surgical ARPs represent the
moderate/severe symptoms from pre-procedure evaluations. Chest standard of care. Endoluminal therapies demonstrated promising
pain and cough decreased by 4 and 14%, respectively, with larger short-term results in patients who suffer from GORD with no hiatal
decreases in voice and dysphagia complaints (25 and 23%, hernia. Further studies of the endoluminal approach are needed to
respectively). PPI use decreased from 81% pre procedure to 45% assess its safety and efficacy, especially in high-risk patients or in
Similar to the NDO Plicator, the Esophyx also cases of recurrence after surgical repair. n
utilises the full-thickness stitch. An anterior partial fundoplication
(270º) is created by attaching the fundus to the anterior and left
Luke Martin is Administrative Chief Resident in general surgery at West Virginia University.
lateral wall of the distal oesophagus using this full-thickness suture.
He is a graduate of the Brody School of Medicine at East Carolina University in Greenville,
Two-year follow-up of 14 of the original 19 patients demonstrated North Carolina, and earned his BSc in chemistry from Guilford College in Greensboro.
no adverse events related to the procedure, relief of heartburn in
93% and elimination of daily PPI use, hiatal hernia and oesophagitis
Thomas Caranasos is a resident in the Department of Surgery at West Virginia University.
He is involved with research in the fields of trauma/critical care, cardiothoracic surgery,
in 71, 60 and 53%, respectively.
acute/chronic pancreatitis and minimally invasive surgery. He completed his first year of
general surgery training at the University of Southern California/LA County Hospital.
The NDO Plicator and Esophyx, as well as the other endoluminal
Ehab Akkary is Director of Minimally Invasive and
therapies, need to be evaluated very carefully in randomised
Bariatric Surgery at West Virginia University School of
studies with larger study groups and long-term comparisons. Study Medicine, where he is in the process of setting up a
groups remain small, and difficulties with recruiting patients for
single-incision laparoscopic surgery (SILS) programme. He
is an active member of the American Medical
researching the endoscopic ARPs persists. Appropriate selection
Association (AMA), the American College of Surgeons
criteria remain stringent and up to 90% of screened potential study (ACS), the American Society for Metabolic and Bariatric
participants have been excluded largely due to issues with PPI use
Surgery (ASMBS), the Society of American
Gastrointestinal Endoscopic Surgeons (SAGES) and the
and large hiatal hernias.
This may identify a significant difficulty in
Society of Laparoendoscopic Surgeons (SLS), among others. He completed a general
the utilisation of endoluminal therapies, as patient selection may surgery residency at North Oakland Hospital in Pontiac and his advanced fellowship
severely limit the number of potential beneficiaries of these
training at Yale University.
procedures. In all probability, they will provide an alternative or
1. Clemente G, D’Ugo D, Granone P, et al., Intraoperative esophagus, Ann Surg, 2001;234:532–8, discussion 538–9. reflux disease, Ann Surg, 1997;225:647–53, discussion 654.
esophageal manometry in surgical treatment of achalasia: 13. Bowers SP, Mattar SG, Smith CD, et al., Clinical and 22. Catarci M, Gentileschi P, Papi C, et al., Evidence-based
a reappraisal, Hepatogastroenterology, 1996;43:1532–6. histologic follow-up after antireflux surgery for Barrett’s appraisal of antireflux fundoplication, Ann Surg, 2004;239:
2. Friedland GW, Progress in radiology: Historical review of esophagus, J Gastrointest Surg, 2002;6:532–8, discussion 325–37.
the changing concepts of lower esophageal anatomy: 430 539. 23. Limpert A, Naunheim K, Partial versus complete
B.C.–1977, AJR Am J Roentgenol, 1978;131:373–8. 14. Anvari M, Allen C, Five-year comprehensive outcomes fundoplication: is there a correct answer?, Surg Clin North
3. Nguyen NQ, Holloway RH, Gastroesophageal reflux evaluation in 181 patients after laparoscopic Nissen Am, 2005;85(3):399–410.
disease, Curr Opin Gastroenterol, 2003;19(4):373–8. fundoplication, J Am Coll Surg, 2003;196:51–7, discussion 24. Triadafilopoulos G, DiBaise JK, Nostrant TT, et al., The
4. Allocca M, Penagini R, Effect of phasic contractions and 57–8, author reply 58–9. Stretta procedure for the treatment of GERD: 6 and 12
tone of the proximal stomach on triggering of transient 15. McKenzie D, Grayson T, Polk HC Jr, The impact of month follow-up of the U.S. open label trial, Gastrointest
lower esophageal sphincter relaxation, Dig Dis Sci, omeprazole and laparoscopy upon hiatal hernia and reflux Endosc, 2002;55:149-156.
2004;49(5):710–14. esophagitis, J Am Coll Surg, 1996;183:413–18. 25. Scientific B, Boston Scientific Recalls ENTERYX Products
5. Oelschlager BK, Eubanks TR, Pellegrini CA, Sabiston Textbook 16. Lundell L, Miettinen P, Myrvold HE, et al., Continued 2005. Available at: www.bostonscientific.com/common_
of Surgery, 17th ed, Townsend, 2004;1151–64. (5-year) follow-up of a randomized clinical study templates/procedureOverview.jsp?
6. Floch NR, Surgical therapy for atypical symptoms of GERD: comparing antireflux surgery and omeprazole in 26. Fockens P, Bruno MJ, Gabbrielli A, et al., The treatment of
patient selection and preoperative evaluation, J Clin gastroesophageal reflux disease, J Am Coll Surg, gastroesophageal reflux disease: multicenter study of the
Gastroenterol, 2000;30:S45–S47. 2001;192:172–9, discussion 179–81. Gatekeeper Reflux Repair System, Endoscopy, 2004;36:
7. Hill LD, Kozarek RA, Kraemer SJ, et al., The 17. Roberts KE, Duffy AJ, Bell RL, Controversies in the 682–9.
gastroesophageal flap valve: In vitro and in vivo treatment of gastroesophageal reflux and achalasia, 27. Pleskow D, Rothstein R, Lo S, et al., Endoscopic full-
observations, Gastrointest Endosc, 1996;44:541–7. World J Gastroenterol, 2006;28(12(20)):3155–61. thickness plication for the treatment of GERD: 12-month
8. Grande L, Culell P, Ros E, et al., Comparison of stationary 18. Spechler SJ, Lee E, Ahnen D, et al., Long-term outcome of follow-up for the North American open-label trial,
vs ambulatory 24-hour pH monitoring systems in medical and surgical therapies for gastroesophageal Gastrointest Endosc, 2005;61:643–9.
diagnosis of gastroesophageal reflux disease, Dig Dis Sci, reflux disease: follow-up of a randomized controlled trial, 28. White B, Jeansonne LO, Cook M, et al., Use of Endoluminal
1993;38:213–19. JAMA, 2001;285:2331–8. Antireflux Therapies for Obese Patients with GERD, Obes
9. Zwischenberger JB, Savage C, Bhutani MS, Sabiston Textbook 19. Lord RV, Kaminski A, Oberg S, et al., Absence of Surg, 2009;19(6):783–7.
of Surgery, 17th ed, Townsend, 2004;1099–1102. gastroesophageal reflux disease in a majority of patients 29. Cadière GB, Van Sante N, Graves JE, et al., Two-year results
10. Lafullarde T, Watson DI, Jamieson G, et al., Laparoscopic taking acid suppression medications after Nissen of a feasibility study on antireflux transoral incisionless
Nissen fundoplication: five-year results and beyond, Arch fundoplication, J Gastrointest Surg, 2002;6:3–9, discussion 10. fundoplication using EsophyX, Surg Endosc, 2009;23(5):
Surg, 2001;136:180–84. 20. Fibbe C, Layer P, Keller J, et al., Esophageal motility in 957–64.
11. Oelschlager BK, Barreca M, Chang L, et al., Clinical and reflux disease before and after fundoplication: a 30. Eckardt AJ, Pinnow G, Pohl H, et al., Antireflux ‘barriers’:
pathologic response of Barrett’s esophagus to prospective, randomized, clinical, and manometric study, problems with patient recruitment for a new endoscopic
laparoscopic antireflux surgery, Ann Surg, 2003;238:458–64, Gastroenterology, 2001;121:5–14 antireflux procedure, Eur J Gastroenterol Hepatol, 2009 Mar 18
discussion 464–6. 21. Laws HL, Clements RH, Swillie CM, A randomized, (Epub ahead of print).
12. Hofstetter WL, Peters JH, DeMeester TR, et al., Long-term prospective comparison of the Nissen fundoplication
outcome of antireflux surgery in patients with Barrett’s versus the Toupet fundoplication for gastroesophageal
10 EUROPEAN GASTROENTEROLOGY & HEPATOLOGY REVIEW
| Page 2
| Page 3
| Page 4
| Page 5
| Page 6
| Page 7
| Page 8
| Page 9
| Page 10
| Page 11
| Page 12
| Page 13
| Page 14
| Page 15
| Page 16
| Page 17
| Page 18
| Page 19
| Page 20
| Page 21
| Page 22
| Page 23
| Page 24
| Page 25
| Page 26
| Page 27
| Page 28
| Page 29
| Page 30
| Page 31
| Page 32
| Page 33
| Page 34
| Page 35
| Page 36
| Page 37
| Page 38
| Page 39
| Page 40
| Page 41
| Page 42
| Page 43
| Page 44
| Page 45
| Page 46
| Page 47
| Page 48
| Page 49
| Page 50
| Page 51
| Page 52
| Page 53
| Page 54
| Page 55
| Page 56
| Page 57
| Page 58
| Page 59
| Page 60
| Page 61
| Page 62
| Page 63
| Page 64
| Page 65
| Page 66
| Page 67
| Page 68
| Page 69
| Page 70
| Page 71
| Page 72
| Page 73
| Page 74
| Page 75
| Page 76